

Open Peer Review on Qeios

Dabrafenib Mesylate

National Cancer Institute

Source

National Cancer Institute. <u>Dabrafenib Mesylate</u>. NCI Thesaurus. Code C128059.

The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Qeios ID: FH3GFH · https://doi.org/10.32388/FH3GFH